J. Safra Sarasin Holding AG Purchases Shares of 18,499 Cencora, Inc. (NYSE:COR)

J. Safra Sarasin Holding AG purchased a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 18,499 shares of the company's stock, valued at approximately $4,156,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC grew its position in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Cencora during the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC increased its holdings in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after buying an additional 69 shares during the last quarter. Kentucky Trust Co bought a new stake in shares of Cencora in the 4th quarter valued at approximately $33,000. Finally, WASHINGTON TRUST Co lifted its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Price Performance

Shares of COR traded up $3.66 during trading hours on Friday, hitting $286.05. 1,815,757 shares of the company were exchanged, compared to its average volume of 1,517,912. The firm has a fifty day simple moving average of $267.20 and a 200-day simple moving average of $248.71. The company has a market capitalization of $55.47 billion, a PE ratio of 40.69, a PEG ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This trade represents a 9.46 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,223 shares of company stock worth $13,580,967. Insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on COR shares. Morgan Stanley set a $288.00 price target on shares of Cencora in a report on Tuesday, April 15th. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Finally, Wells Fargo & Company raised their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $284.55.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.